John R. Mackey

Active 1996–2025

161
Papers
36,159
Citations
101
h-index
157
i10-index

Citations

Citations per year for John R. Mackey1998: 3 citations1999: 5 citations2000: 13 citations2001: 51 citations2002: 53 citations2003: 87 citations2004: 121 citations2005: 124 citations2006: 171 citations2007: 173 citations2008: 230 citations2009: 263 citations2010: 325 citations2011: 374 citations2012: 468 citations2013: 492 citations2014: 463 citations2015: 540 citations2016: 475 citations2017: 417 citations2018: 361 citations2019: 1,148 citations2020: 1,065 citations2021: 972 citations2022: 714 citations2023: 539 citations2024: 776 citations2025: 357 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,413 citing papers, 24.7% of this breakdownChina: 1,041 citing papers, 7.5% of this breakdownCanada: 1,038 citing papers, 7.5% of this breakdownUnited Kingdom: 921 citing papers, 6.7% of this breakdownItaly: 739 citing papers, 5.4% of this breakdownGermany: 590 citing papers, 4.3% of this breakdownFrance: 495 citing papers, 3.6% of this breakdownAustralia: 476 citing papers, 3.5% of this breakdownSpain: 406 citing papers, 2.9% of this breakdownNetherlands: 354 citing papers, 2.6% of this breakdownJapan: 330 citing papers, 2.4% of this breakdownSouth Korea: 309 citing papers, 2.2% of this breakdown
0%24.7%Other 26.7%

Fields

  • Medicine63%
  • Biochemistry, Genetics and Molecular Biology28.6%
  • Immunology and Microbiology2.3%
  • Computer Science0.9%
  • Engineering0.8%
  • Materials Science0.8%
  • Other3.6%

Topics

  • Cancer survivorship and care5%
  • HER2/EGFR in Cancer Research3.7%
  • Breast Cancer Treatment Studies3.7%
  • Cancer Treatment and Pharmacology2.9%
  • Nutrition and Health in Aging2.9%
  • Chemotherapy-induced cardiotoxicity and mitigation2.6%
  • Other79.2%

Coauthors

All papers

Open in search
  1. Adjuvant Trastuzumab in HER2-Positive Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2011 cited by 2,775

  2. Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2022 cited by 223

  3. The clonal and mutational evolution spectrum of primary triple-negative breast cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Malachi Griffith, Annie Moradian, Siwei Cheng, Gregg B. Morin, Peter H. Watson, Karen A. Gelmon, Stephen Chia, Suet‐Feung Chin, Christina Curtis, Oscar M. Rueda, Paul D.P. Pharoah, Sambasivarao Damaraju, John R. Mackey, Kelly Hoon, Timothy T. Harkins, Vasisht Tadigotla, Mahvash Sigaroudinia, Philippe Gascard, Thea D. Tlsty, J Costello, Irmtraud M. Meyer, Connie J. Eaves, Wyeth W. Wasserman, Steven J.M. Jones, David G. Huntsman, Martin Hirst, Carlos Caldas, Marco A. Marra, Samuel Aparício - Nature 2012 cited by 2,036

  4. Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

    Authors: , , , , , , , , , - Clinical Cancer Research 2009 cited by 1,111

  5. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Toru Watanabe, Greg Yothers, Ke‐Da Yu, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Lucy Davies, Frances Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Lui, Zulian Lui, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Aman U. Buzdar, Vera J. Suman, Kelly K. Hunt, Robert Leonard, Janine Mansi, Catherine Delbaldo, Pascal Piedbois, Emmanuel Quinaux, Christian Fesl, Michael Gnant, Lidija Sölkner, Guenther G. Steger, Hans Petter Eikesdal, Per Eystein Lønning, Valerie Bée, Helena Fung, John R. Mackey, Miguel Martín, Michael F. Press, Evandro de Azambuja, Richard D. Gelber, Meredith M. Regan, Angelo Di Leo, Veerle Van Dooren, J.-M. Nogaret, John M.S. Bartlett, Bingshu E. Chen, Karen A. Gelmon, Paul E. Goss, Mark N. Levine, Wendy R. Parulekar, Kathleen I. Pritchard, Lois E. Shepherd, Donald A. Berry, Constance Cirrincione, Lawrence N. Shulman, Eric P. Winer, Rebecca Gelman, Jay R. Harris, Craig Henderson, Charles L. Shapiro, Peer Christiansen, Marianne Ewertz, Henning T. Mouridsen, Elise Van Leeuwen, Sabine C. Linn, Annelot G.J. van Rossum, Harm van Tinteren and 136 more - The Lancet 2023 cited by 189

  6. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christina Davies, Frances Duane, Vaughan Evans, Lucy Gettins, Jon Godwin, Robert K. Hills, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Yaochen Wang, Zhe Wang, Peter A. Fasching, Nadia Harbeck, Pascal Piedbois, Michael Gnant, Guenther G. Steger, Angelo Di Leo, Stella Dolci, Prue Francis, Denis Larsimont, J.-M. Nogaret, C. Philippson, Martine Piccart, Sabine C. Linn, Petronella G.M. Peer, Vivianne C. G. Tjan‐Heijnen, S.B. Vliek, John R. Mackey, Dennis Slamon, John M.S. Bartlett, Vivien Bramwell, Bingshu E. Chen, Stephen Chia, Karen A. Gelmon, Paul E. Goss, Mark N. Levine, Wendy R. Parulekar, Joseph L. Pater, Eileen Rakovitch, Lois E. Shepherd, Dongsheng Tu, Timothy J. Whelan, Donald A. Berry, Gloria Broadwater, Constance Cirrincione, Hyman B. Muss, Raymond L. Weiss, Yi Shan, Yong fu Shao, Xiang Wang, Binghe Xu, Dongbing Zhao, Harry Bartelink, Nina Bijker, Jan Bogaerts, Fátima Cardoso, Tanja Čufer, Jean‐Pierre Julien, Philip Poortmans, Emiel J. Rutgers, Cornelis J.�H. van de Velde, Eva Carrasco, Miguel Ángel Seguí, Jens‐Uwe Blohmer, Serban Dan Costa, Bernd Gerber and 67 more - The Lancet 2019 cited by 394

  7. Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2007 cited by 1,172

  8. Incident Cardiovascular Disease Among Adults With Cancer

    Authors: , , , , , , - JACC CardioOncology 2022 cited by 183

  9. Metabolic Modulation of Glioblastoma with Dichloroacetate

    Authors: , , , , , , , , , , , , - Science Translational Medicine 2010 cited by 715

  10. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

    Authors: , , - British Journal of Cancer 2008 cited by 651

  11. Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 2012 cited by 437

  12. Effects of Exercise during Adjuvant Chemotherapy on Breast Cancer Outcomes

    Authors: , , , , , , , , , - Medicine & Science in Sports & Exercise 2014 cited by 267

  13. Targeting N-myristoylation for therapy of B-cell lymphomas

    Authors: , , , , , , , , , , , , , , , , , - Nature Communications 2020 cited by 66

  14. Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 850

  15. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity

    Authors: , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 401

  16. Effects of Exercise Dose and Type During Breast Cancer Chemotherapy: Multicenter Randomized Trial

    Authors: , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2013 cited by 301

  17. Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes

    Authors: , , , , , - Journal of Clinical Oncology 2003 cited by 756

  18. Nucleoside analogues and nucleobases in cancer treatment

    Authors: , , - The Lancet Oncology 2002 cited by 606

  19. Presentation and management of docetaxel-related adverse effects in patients with breast cancer

    Authors: , - Cancer Management and Research 2014 cited by 214

  20. Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial

    Authors: , , , , , , , , , - Breast Cancer Research and Treatment 2016 cited by 169

  21. Early Breast Cancer Therapy and Cardiovascular Injury

    Authors: , , , , - Journal of the American College of Cardiology 2007 cited by 451

  22. Association of FABP5 Expression With Poor Survival in Triple-Negative Breast Cancer

    Authors: , , , , , - American Journal Of Pathology 2011 cited by 165

  23. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2016 cited by 104

  24. Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

    Authors: , , , , , , , , - Journal of Clinical Oncology 2008 cited by 407